486 related articles for article (PubMed ID: 9659858)
21. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M
Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275
[TBL] [Abstract][Full Text] [Related]
22. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.
Kapur S; Zipursky R; Jones C; Remington G; Houle S
Am J Psychiatry; 2000 Apr; 157(4):514-20. PubMed ID: 10739409
[TBL] [Abstract][Full Text] [Related]
23. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
Kapur S; Seeman P
Am J Psychiatry; 2001 Mar; 158(3):360-9. PubMed ID: 11229973
[TBL] [Abstract][Full Text] [Related]
24. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.
Lavalaye J; Linszen DH; Booij J; Reneman L; Gersons BP; van Royen EA
Psychiatry Res; 1999 Nov; 92(1):33-44. PubMed ID: 10688158
[TBL] [Abstract][Full Text] [Related]
25. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
Remington G; Mamo D; Labelle A; Reiss J; Shammi C; Mannaert E; Mann S; Kapur S
Am J Psychiatry; 2006 Mar; 163(3):396-401. PubMed ID: 16513859
[TBL] [Abstract][Full Text] [Related]
26. Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine.
Moresco RM; Cavallaro R; Messa C; Bravi D; Gobbo C; Galli L; Lucignani G; Colombo C; Rizzo G; Velonà I; Smeraldi E; Fazio F
J Psychopharmacol; 2004 Sep; 18(3):355-65. PubMed ID: 15358979
[TBL] [Abstract][Full Text] [Related]
27. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
[TBL] [Abstract][Full Text] [Related]
28. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone.
Nyberg S; Farde L; Eriksson L; Halldin C; Eriksson B
Psychopharmacology (Berl); 1993; 110(3):265-72. PubMed ID: 7530376
[TBL] [Abstract][Full Text] [Related]
29. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
Arakawa R; Okumura M; Ito H; Takano A; Takahashi H; Takano H; Maeda J; Okubo Y; Suhara T
J Clin Psychiatry; 2010 Sep; 71(9):1131-7. PubMed ID: 20361897
[TBL] [Abstract][Full Text] [Related]
30. Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs. Review of D2 and 5-HT2 receptor occupancy studies and clinical response.
Nyberg S; Nakashima Y; Nordström AL; Halldin C; Farde L
Br J Psychiatry Suppl; 1996 May; (29):40-4. PubMed ID: 8733822
[No Abstract] [Full Text] [Related]
31. A new framework for investigating antipsychotic action in humans: lessons from PET imaging.
Kapur S
Mol Psychiatry; 1998 Mar; 3(2):135-40. PubMed ID: 9577837
[TBL] [Abstract][Full Text] [Related]
32. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine.
Kapur S; Roy P; Daskalakis J; Remington G; Zipursky R
Am J Psychiatry; 2001 Feb; 158(2):311-4. PubMed ID: 11156818
[TBL] [Abstract][Full Text] [Related]
33. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients.
Nordström AL; Farde L
J Clin Psychopharmacol; 1998 Aug; 18(4):305-10. PubMed ID: 9690696
[TBL] [Abstract][Full Text] [Related]
34. Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.
Iwata Y; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Plitman E; Chung JK; Mar W; Gerretsen P; Pollock BG; Mulsant BH; Rajji TK; Mamo DC; Graff-Guerrero A
J Clin Psychiatry; 2016 Dec; 77(12):e1557-e1563. PubMed ID: 28086010
[TBL] [Abstract][Full Text] [Related]
35. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.
Nordström AL; Farde L; Wiesel FA; Forslund K; Pauli S; Halldin C; Uppfeldt G
Biol Psychiatry; 1993 Feb; 33(4):227-35. PubMed ID: 8097114
[TBL] [Abstract][Full Text] [Related]
36. In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine.
Raedler TJ; Knable MB; Lafargue T; Urbina RA; Egan MF; Pickar D; Weinberger DR
Psychiatry Res; 1999 Apr; 90(2):81-90. PubMed ID: 10482380
[TBL] [Abstract][Full Text] [Related]
37. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients.
Trichard C; Paillère-Martinot ML; Attar-Levy D; Recassens C; Monnet F; Martinot JL
Am J Psychiatry; 1998 Apr; 155(4):505-8. PubMed ID: 9545996
[TBL] [Abstract][Full Text] [Related]
38. Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.
Nakajima S; Uchida H; Bies RR; Caravaggio F; Suzuki T; Plitman E; Mar W; Gerretsen P; Pollock BG; Mulsant BH; Mamo DC; Graff-Guerrero A
Schizophr Bull; 2016 Jan; 42(1):212-9. PubMed ID: 26221049
[TBL] [Abstract][Full Text] [Related]
39. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
40. Implications of brain imaging for the management of schizophrenia.
Nyberg S; Nilsson U; Okubo Y; Halldin C; Farde L
Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S15-20. PubMed ID: 9690965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
